Eli Lilly announced that its investigational biologic EBGLYSS (lebrikizumab‑lbkz) achieved positive topline results in the Phase 3 ADorable‑1 trial for children with moderate‑to‑severe atopic dermatitis. The study enrolled 363 patients aged six months to 18 years and showed that 63 % achieved meaningful skin improvement (EASI‑75) and 44 % reached clear or almost clear skin (IGA 0,1) at week 16. Near‑complete clearance (EASI‑90) was achieved by 39 % of participants, and 35 % reported significant itch relief.
EBGLYSS is a selective interleukin‑13 (IL‑13) inhibitor that was approved in the United States, Japan, and Canada in 2024 and in the European Union in 2023 for adults and adolescents 12 years and older weighing at least 88 pounds. The ADorable‑1 results support a potential label expansion to younger children, including infants as young as six months, which would broaden the drug’s addressable market and strengthen Lilly’s dermatology portfolio.
The atopic dermatitis market is highly competitive, with Dupixent (dupilumab) from Sanofi and Regeneron dominating the pediatric segment. EBGLYSS’s selective IL‑13 inhibition offers a distinct mechanism that may provide a therapeutic advantage. In the United States, an estimated 9.6 million children are affected by atopic dermatitis, and roughly one‑third have moderate‑to‑severe disease, underscoring the unmet need that a pediatric indication could address.
Safety data from the trial were consistent with the adult and adolescent studies, with no new safety signals. Common adverse events included upper respiratory tract infections and nasopharyngitis, and no injection‑site pain was reported.
"Despite the high prevalence of moderate‑to‑severe atopic dermatitis in infants and young children, therapeutic options remain limited. The topline results from ADorable‑1 suggest that selective IL‑13 inhibition with lebrikizumab may offer robust skin clearance and meaningful pruritus reduction in this younger patient population," said Dr. Amy Paller, an investigator in the ADorable study.
The positive Phase 3 data position Eli Lilly to pursue regulatory submissions for a pediatric label, potentially unlocking a new revenue stream and reinforcing its position in the dermatology market. The results also reinforce the safety profile of EBGLYSS, supporting confidence in its continued development across multiple indications.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.